Literature DB >> 1848639

Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer.

J N Munck1, E Cvitkovic, J D Piekarski, E Benhamou, G Recondo, M Bachouchi, E Tellez-Bernal, B Luboinski, F Eschwege, P Wibault.   

Abstract

Pretherapeutic identification of patients likely to benefit from neoadjuvant chemotherapy for head and neck epidermoid cancer is of interest. We retrospectively analyzed the pretherapeutic computed tomographic (CT) scans of lymph nodes of 70 patients with head and neck cancer. All 70 patients were clinically classified as having stage IV disease. The purpose of our analysis was to compare the prognostic value of CT node density with that of the following factors: age, T and N categories, Eastern Cooperative Oncology Group performance status, tumor site, histopathologic type of disease [squamous cell carcinoma (SCC) or undifferentiated carcinoma of nasopharyngeal type (UNCT)], and type of local-regional treatment. A simple two-grade nodal density grading system was devised. The density of normal adjacent muscle was chosen as the density standard. A node was classified grade 1 if less than 33% of the node consisted of hypodense zones. A node was classified grade 2 if more than 33% of the node consisted of hypodense zones. Patients with grade 1 nodes had a complete response rate of 68% (21/31) compared with 8% (3/39) for those with grade 2 nodes (P less than .0001). The only other factor associated with complete node response was UCNT (P less than .03). However, node density remained the significant prognostic factor after adjustment for histopathologic type. Follow-up ranged from 16 to 44 months, with a median of 29 months. Patients with grade 1 nodes had a median survival time of 32 months versus 13 months for those with grade 2 nodes (P less than .01). A prospective study should validate the prognostic value of CT node density and its possible use in determining optimal multimodal therapy for advanced head and neck cancers.

Entities:  

Mesh:

Year:  1991        PMID: 1848639     DOI: 10.1093/jnci/83.8.569

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer.

Authors:  Peter A Paximadis; Michael E Christensen; Greg Dyson; Dev P Kamdar; Ammar Sukari; Ho-Sheng Lin; George H Yoo; Harold E Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

2.  Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy.

Authors:  Giuseppe Sanguineti; Francesco Ricchetti; Binbin Wu; Nishant Agrawal; Christine Gourin; Harold Agbahiwe; Shanthi Marur; Stefania Clemente; Todd McNutt; Arlene Forastiere
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

3.  Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.

Authors:  Thomas Kuhnt; Arndt-Christian Mueller; Tanja Pelz; Gabriele Haensgen; Marc Bloching; Sabrina Koesling; Johannes Schubert; Juergen Dunst
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

4.  Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Authors:  Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2017-12-19       Impact factor: 6.280

Review 5.  What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck.

Authors:  Michiel W M van den Brekel; Jonas A Castelijns
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

6.  Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.

Authors:  Lu-Lu Zhang; Guan-Qun Zhou; Yi-Yang Li; Ling-Long Tang; Yan-Ping Mao; Ai-Hua Lin; Jun Ma; Zhen-Yu Qi; Ying Sun
Journal:  Cancer Med       Date:  2017-10-16       Impact factor: 4.452

7.  Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: Relationship with human papillomavirus status and failure patterns.

Authors:  Yu-Han Huang; Chih-Hua Yeh; Nai-Ming Cheng; Chien-Yu Lin; Hung-Ming Wang; Sheung-Fat Ko; Cheng-Hong Toh; Tzu-Chen Yen; Chun-Ta Liao; Shu-Hang Ng
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

8.  Influence of Cervical Node Necrosis of Different Grades on the Prognosis of Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy.

Authors:  Lu-Lu Zhang; Jia-Xiang Li; Guan-Qun Zhou; Ling-Long Tang; Jun Ma; Ai-Hua Lin; Zhen-Yu Qi; Ying Sun
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.